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Regulation of apoptosis by Bcl-2 family proteins is a paradigm for complex protein-protein and
protein-membrane systems. Elucidating the molecular mechanisms of these interactions in vitro
in live cells and in animal studies has been significantly enhanced by using fluorescence
techniques.Apoptosis and Membranes: The Problem Posed
Ironically, the organelle that helps to provide cells with energy to
live also serves as a platform to actively initiate cell death. Unlike
forms of cell death triggered by mitochondrial dysfunction,
during apoptosis, the signals that regulate the fate of the cell
are integrated at functioning mitochondria and govern the irre-
versible step of mitochondrial outer membrane permeabilization
(MOMP). Upon induction of apoptosis, the integrity of the mito-
chondrial outer membrane (MOM) is breached, resulting in
the release of cytochrome c and other intermembrane space
proteins into the cytoplasm. The released proteins trigger the
activation of multiple pathways that result in the demise of the
cell. Thus, a series of protein-protein and protein-membrane
interactions control a process that is largely mechanical and
that occurs in membranes.
The Bcl-2 family of proteins plays a major role in both sensing
different types of cellular stress and regulating MOMP. To
accomplish these tasks, different members of the Bcl-2 family
are located in multiple parts of the cell and function as both cyto-
plasmic and membrane proteins by adopting distinct conforma-
tions that dictate their function (Figure 1A). Because of the
distributed nature of this regulation and the involvement of
complex membrane interactions, this process deviates from
the classical ‘‘lock and key’’ enzyme-substrate interactions
that are fundamental to biochemistry and pharmacology. More-
over, even though apoptosis involves dramatic cell morphology
changes, the techniques of observational molecular biology are
not easily applicable to the analysis of apoptosis because it
comprises a series of hierarchical stochastic events governed
by complex reversible equilibria. Yet together, both approaches
have led to tremendous insights (and blind alleys) in our quest to
understand and therapeutically exploit apoptosis.
As Bcl-2 family proteins target to both the endoplasmic retic-
ulum (ER) and the mitochondria, the cell fate decision is regu-
lated by both complex binding equilibria between the proteins
and the local concentration of active binding partners, which is
very different at the two organelles (Figure 1A). Moreover, active
Bax, a proapoptotic Bcl-2 family member, has also been foundsequestered at the Golgi in embryonic stem cells, providing
a large pool of death effectors primed to cause MOMP upon
the first indication of DNA damage. Therefore, Golgi are another
membrane system at which the Bcl-2 family proteins can
interact, contributing further to the complexity of regulating
apoptosis (Dumitru et al., 2012). Thus, for the Bcl-2 family, the
crucial role played by membranes makes the traditional
approach of examining the underpinnings of particular cellular
phenotypes with ‘‘grind and find’’ biochemistry problematic. To
bridge this gap, several in vitro model systems of varying
complexity have been exploited, and in this Review, we will high-
light some of the insights gained by this approach, with a focus
on studies in which fluorescence techniques are being used to
integrate observations from purified proteins with those from
live cells and even animals. The ongoing theme is that molecular
characterization of phenotypes observed at a cellular, tissue, or
organism level requires rigorous analysis with increasingly
sophisticated model systems.
In Vitro Models Elucidate the Core Mechanisms
The oncogene bcl2was originally discoveredmore than 20 years
ago as a chromosomal translocation partner in human follicular B
cell lymphoma that resulted in the protein being overexpressed.
Experiments using transgenic mice and overexpressing cell lines
demonstrated that its function was to inhibit the then novel
process of apoptosis. By using Bcl-2 as a binding target in immu-
noprecipitation studies and analyzing other cellular models of
apoptosis, many other proteins related to Bcl-2 have been
found, including those with the opposite function of promoting
apoptosis. The Bcl-2 family was subsequently divided into three
groups based on function and the presence of conserved Bcl-2
homology (BH) regions. The proapoptotic proteins comprise two
groups: those with multiple BH regions, such as Bax and Bak,
and those that contain only the BH3 region. Bax and Bak
undergo complex conformational changes that result in their
oligomerization in the MOM and, in turn, cause MOMP, thereby
releasing apoptogenic factors such as cytochrome c and SMAC.
These conformational changes are initiated by binding BH3-onlyCell 151, December 7, 2012 ª2012 Elsevier Inc. 1179
Figure 1. Interactions of Bcl-2 Family Proteins Quantified Using Fluorescence
The Bcl-2 family of proteins modulates apoptosis through a series of intricate protein-protein and protein-membrane interactions that exist in equilibrium.
Fluorescence-based assays uniquely permit quantitative analyses in real time of interaction mechanisms that govern the biology of complex systems at
membranes.
(A) Bcl-2 family proteins are located at multiple membranes within the cell and undergo a series of complex interactions that regulate apoptosis. Multiregion Bcl-2
family proteins (red cylinders) are found at ER andmitochondrial membranes, with a small subset also at Golgi. BH3-only proteins (yellow) are found inmany areas
of the cell and are recruited to single (squares, ER; triangles, mitochondria) or multiple subcellular membranes (circles). The specific sets of binding partners are
different at each subcellular membrane (blue squares, ER; blue triangles, mitochondria). The balance of interactions between all of these proteins governs the fate
of the cell.
(B) Attaching fluorescent dyes to cBid (DAC, donor) and Bax (NBD, acceptor) and measuring FRET via a decrease in donor fluorescence in real time reveals that
a cBid-Bax interaction requires the presence of a membrane. Such measurements allow both affinities and the kinetics of the interaction to be quantified.
(C) Fluorescence techniques can be used to extend in vitro results to live cells by expressing Bcl-2 family proteins fused with fluorescent proteins and
measuring protein-protein interactions and binding dynamics by FRET. The observed FRET FLIM efficiency increases (according to the color scale) as
the acceptor:donor ratio increases until the donors are saturated by bound acceptors generating a binding curve, permitting the determination of binding
constants.proteins such as Bid, Bim, and Puma, which are termed activa-
tors. The third group includes the antiapoptotic proteins such as
Bcl-2, Bcl-XL, and Mcl-1 that contain three or four BH regions
and prevent MOMP by binding either activator BH3-only
proteins or activated Bax and Bak. Bad and Noxa are examples
of sensitizer BH3-only proteins that promote apoptosis indirectly
by competing for binding to antiapoptotic proteins, conse-
quently displacing activated Bax/Bak or activator BH3-only
proteins to allow Bax/Bak activation. Thus, the core mechanism
of apoptosis includes the conformational changes in Bax or Bak1180 Cell 151, December 7, 2012 ª2012 Elsevier Inc.that permit MOMP and interactions with other Bcl-2 family
members that either enhance or inhibit this process.
Though studies using immunoprecipitation of whole-cell
lysates identified some of the potential interactions noted in
the scheme above, this method has limitations, as nonionic
detergents such as Triton cause heterodimerization between
Bax and Bcl-2 that does not occur constitutively in situ;
conversely, CHAPS dramatically decreases Bax binding to Bid.
To circumvent these problems, one can study interactions
between purified proteins. However, many of these proteins
have hydrophobic C-terminal tails, which considerably compli-
cates purification of full-length and functional proteins, and in
the case of some proteins that are constitutively localized to
intracellular membranes (e.g., Bcl-2 and Bak) or are difficult to
purify for various reasons (e.g., Mcl-1), this has not yet been
accomplished. An alternative approach was to use peptides
and/or truncated versions of Bcl-2 family proteins lacking the
C-terminal tail for biophysical and structural studies, including
nuclear magnetic resonance (NMR) and crystallography. These
approaches generated data indicating that Bcl-2 family proteins
function as ligand-receptor pairs relying on the BH3 region of one
protein binding to a hydrophobic groove, termed the BH3
pocket, on the other member. Beyond this consensus, the limi-
tations of the approaches resulted in both controversy and
confusion in the field.
Many of these problems have been bypassed in an elegant
series of studies (Kim et al., 2009) using a detergent-free system
with full-length proteins synthesized by in vitro translation, which
confirmed the hierarchical nature and presumed order of interac-
tions as indicated above. These experiments also confirmed Bid,
Bim, and PUMA (the latter previously contentious) as activators
of Bax or Bak and demonstrated that antiapoptotic proteins
bound to all three activators but differentially to sensitizer-
BH3-only proteins. For example, the sensitizer Bad displaced
activator BH3-only proteins from Bcl-2 and Bcl-XL, but not
Mcl-1, whereas the sensitizer Noxa was effective against
Mcl-1, but not Bcl-2/Bcl-XL.
However, it is not possible to study the kinetics of or
to measure the affinity of binding with such an approach.
Therefore, we developed an in vitro system using liposomes
of defined composition and included fluorescently labeled
versions of the relevant recombinant full-length proteins. This
system possesses several unique advantages. First, by using
Fo¨rster resonance energy transfer (FRET), the binding of the
proteins to each other and to membranes could be measured
quantitatively at physiologic concentrations in an environment
with liposomes that mimic the composition of the mitochondrial
membrane (Figure 1B). Furthermore, by using combinations
of fluorophores whose excitation/emission spectra allowed
simultaneous analyses, the interactions could be ordered in
real time. Finally, using fluorescent dyes for which the emission
is sensitive to the presence of water allowed the insertion of
these proteins into the hydrophobic environment of the
membrane to be monitored (Lovell et al., 2008). The data indi-
cated that the permeabilization of MOM by tBid-activated Bax
proceeds in a discrete series of steps: caspase-mediated
cleavage of the BH3-only protein Bid resulted in the cleaved
protein cBid, containing a p7 and p15 fragment, binding rapi-
dly to membranes. This binding causes the amino-terminal p7
fragment to dissociate from the membrane-bound form of the
p15 fragment, tBid. Membrane-bound tBid, which contains
the BH3 region, then binds to Bax, causing it to insert into the
membrane. Studies of the binding between mutant proteins
suggest that the basis of binding on themembrane likely involves
structural changes in tBid and the N-terminal helix of Bax,
which stabilizes the C-terminal transmembrane helix in the
BH3 pocket by masking this binding surface on Bax in solution
(Kim et al., 2009). After binding by tBid, the interaction withBax is diminished, allowing the transmembrane helix to disen-
gage from the pocket and target Bax to membranes. Bax then
oligomerizes in the MOM, permeabilizing it and releasing apop-
togenic factors (e.g., cytochrome c, SMAC) from the intermem-
brane space.
Using fluorescence to measure the rates of these individual
interactions revealed that insertion of Bax into the membrane
was the rate-limiting step for MOMP (Lovell et al., 2008). The
antiapoptotic proteins interfere with MOMP at several steps.
Similar to Bax, Bcl-XL is recruited to the membrane by tBid,
and by binding to it at this location, Bcl-XL prevents tBid from
interacting with Bax (Billen et al., 2008). However, Bad binding
to Bcl-XL frees tBid to activate Bax (Lovell et al., 2008). This
exchange of binding partners is governed by the affinities and
therefore the relative abundance of the membrane-bound
proteins, both factors that are hard to measure in cells. That
the various interacting partners are exchangeable and in equilib-
rium is the mechanistic basis for Bad functioning as a sensitizer.
Bcl-XL interacts with Bax in multiple ways. It binds directly to
membrane-inserted, activated Bax, thereby preventing propa-
gation of the oligomers required for MOMP. Perhaps more
importantly, Bcl-XL also causes the retrotranslocation of Bax
from the MOM to the cytoplasm before Bax attains the
membrane-inserted conformation competent for oligomeriza-
tion (Edlich et al., 2011). In this way, Bcl-XL intercedes very early
in the multistep Bax activation sequence to shuttle peripherally
bound Bax from the MOM to the cytoplasm, preventing inci-
dental Bax activation in healthy cells due to Bax proximity to
the membrane.
The above model of how the Bcl-2 family regulates MOMP is
based on observations from a variety of cell-free systems
made by many laboratories. Collectively, the results emphasize
the importance of protein-protein and protein-membrane inter-
actions. Binding to membranes shifts the equilibria between
the conformations of Bcl-2 proteins. Therefore, the function
of the proteins is markedly different in the cytoplasm and within
the membrane. To reflect these observations, the model was
given the name ‘‘embedded together’’ (Leber et al., 2010).
The Next Step: Regulation of the Core Mechanism
in Cells
Because of the paramount importance of dysregulated
apoptosis in many disease processes (too little in cancer, too
much in neurodegenerative diseases and ischemia), under-
standing the core mechanism is critical for drug development.
The Bcl-2 family is considered to be an excellent target for elicit-
ing or enhancing an anticancer response because of a large
body of cell-based evidence indicating that cancer cells are
‘‘addicted’’ to the presence of antiapoptotic proteins (i.e., they
are required for ongoing cellular survival; Ni Chonghaile and
Letai, 2008). Based on structural studies, initial small-molecule
screens focused on disrupting the interaction between peptides
corresponding to BH3 regions and truncated versions of Bcl-2
family proteins. Because such assays only partially mimic the
in vivo environment of these proteins, it is not surprising that
few of the first generation of compounds actually hit their target
in cells. In an elegant series of experiments testing these
compounds using cell lines with both Bax and Bak knockedCell 151, December 7, 2012 ª2012 Elsevier Inc. 1181
out as controls for cell death via nonapoptotic mechanisms, only
ABT-737 (a peptidomimetic based on the Bad BH3 region) killed
cells primarily by inducing apoptosis (Vogler et al., 2009). An
orally available form of this drug (ABT-263, Navitoclax; Tse
et al., 2008) has rapidly moved into clinical trials for cancer,
and consistent with the differential binding properties of Bad to
antiapoptotic proteins observed in vitro, the presence of Mcl-1
in the tumor mediates resistance to the drug.
Recent sophisticatedmurinemodels of lymphoma addicted to
specific antiapoptotic Bcl-2 family members have suggested an
additional Achilles’ heel: ABT-737 was not able to kill tumors
dependent on Bcl-XL inhibiting the BH3-only activator Bim
(Me´rino et al., 2012). Current animal studies shed no light on
molecular mechanisms, and this feature of ABT-737 could not
have been predicted from previous structural studies with
peptides and protein fragments. However, the finding was
independently predicted in a cellular model system using fluo-
rescence lifetime imaging microscopy (FLIM) with fluorescent
proteins functioning as FRET pairs fused to different Bcl-2 family
members (Aranovich et al., 2012,). By measuring the lifetime
decrease of FRET donor Venus in cells stably expressing
Venus-Bcl-XL and expressing different (but measurable)
amounts of mCherry acceptor (mCherry-Bad, -tBid, or -Bim), it
was possible to generate a binding curve and thereby link
biochemical observations with molecular mechanisms for
proteins in live cells (Figure 1C). Relative Kd values can then
be calculated in the presence or absence of a drug to test the
effects of exogenous agents on the interaction. Using this
approach, it was shown that ABT-737 did not displace Bim
from Bcl-XL but was effective at disrupting interactions with
tBid and Bad. As an explanation for this difference, it was noted
that mutations in the BH3 regions that disrupted the binding of
tBid or Bad to Bcl-XL (and to Bcl-2) did not affect Bim binding
to Bcl-XL. These results strongly suggest that, in its physiologic
membrane environment, Bim binds to Bcl-XL by a novel
mechanism using other regions besides the traditional BH3
region, which confers its resistance to ABT-737 and ABT-263
(Aranovich et al., 2012; Liu et al., 2012). Moreover, this approach
provides a means for identifying the residues required for
protein-protein interactions in live cells, indicating that FRET-
based FLIM can effectively link studies using purified proteins
and analyses in live cells to reveal novel insights in biochemistry
and pharmacology.
Small molecules and fluorescence have been used to link cell-
free observations with the activity of proteins in cells. One
example comes from studies of the novel binding site for
a stapled Bim BH3 a-helical peptide on purified Bax. The binding
site identified, located opposite of the canonical BH3 pocket, is
referred to as the rear pocket (Gavathiotis et al., 2008). Using
a competitive fluorescence polarization assay and a library of
small molecules predicted to dock to the rear pocket of Bax,
a Bax-specific activator was identified that does not show
appreciable affinity for the antiapoptotic proteins or Bak. This
activator can only cause apoptosis in Bax-containing cells, illus-
trating how in vitro studies can be used to identify a specific
protein mechanism(s) and can thereby lead to the development
of small molecules that can manipulate the core mechanism in
live cells (Gavathiotis et al., 2012).1182 Cell 151, December 7, 2012 ª2012 Elsevier Inc.Cell Death and Survival beyond the Core Mechanism
of MOMP
Beyond the canonical pathways of BH3-only proteins sensing
different types of cell stress and then activating Bax/Bak at the
MOM, other cellular processes regulated by the Bcl-2 family
also prime the cell for death. Much attention has been paid to
the ER as a source of these pathways (reviewed in Heath-Engel
et al., 2008).
The ER is the platform on which Bcl-2 regulates autophagy by
interactingwith Beclin 1, an autophagy promoter (Pattingre et al.,
2005). The development of fluorescent protein fusions for the
autophagy regulatory protein LC3 greatly facilitated the exami-
nation of autophagy at the molecular level in live cells, suggest-
ing that this process is amenable to the precise ordering of
regulatory events at membranes by using fluorescence tech-
niques similar to the studies investigating MOMP described
above. An obvious goal of these studies would be to reveal the
molecular mechanisms that switch autophagy from a cell
survival to a cell death process.
Calcium is one of the important mediators of intracellular
signals, emanating from the ER that is modulated by the Bcl-2
family (He et al., 1997). Sudden changes in calcium concentra-
tions within the cell can trigger apoptosis, but it is unknown
whether cell death is triggered via a sudden decrease or increase
calcium levels within the ER or mitochondria, respectively. Addi-
tionally, the calcium uniporter on the MOM has a low affinity for
calcium, and it was unclear how it could respond to calcium
leakage from the ER during signaling or stress, as the measured
global increase in cytoplasmic calcium was not enough to allow
calcium import into the mitochondria. Recently, an important
facet of this intraorganellar communication has been elucidated
in live cells via fluorescence imaging measurements. Using
a complex system with multiple fluorophores that allowed
simultaneous measurements of the size of the ER-mitochondrial
contacts and the local concentration of calcium at these points,
experiments were conducted in cells that unequivocally demon-
strated the existence of microdomains between these organelles
(Csorda´s et al., 2010). Furthermore the high local concentration
of calcium caused by stimulation of IP3 receptors, which
can be regulated by Bcl-2 at the ER, was enough to allow import
of calcium into the mitochondrion. The stage is now set to
precisely measure these changes, determine the magnitude of
the response required to elicit mitochondrial dysfunction and
cell death, and resolve how the Bcl-2 family can regulate this
process.
Aside from interactions at different organelles, other mecha-
nisms that modulate the core protein-protein interactions
governing MOMP include posttranslational modifications of
the component proteins (reviewed in Kutuk and Letai, 2008).
Under normal cellular conditions, Bim is located on microtu-
bules. However, upon induction of apoptosis, Bim is phosphor-
ylated by JNK1 releasing it from microtubules, whereupon it
targets to the MOM and activates Bax and Bak, leading to
MOMP and apoptosis. Interestingly, phosphorylation of other
Bcl-2 family members results in inhibition of apoptosis. Phos-
phorylation of Bad by AKT promotes Bad interaction with 14-3-
3 proteins, preventing the induction of apoptosis. AKT can also
phosphorylate Bax, resulting in its inhibition via an unknown
mechanism. Although functionally important posttranslational
modifications are generally identified using cells or tissues,
determining how they affect the core molecular mechanisms of
protein function requires the use of sophisticated cell-free
systems. Deciphering the molecular mechanism is particularly
important for proteins like Bax that are potential therapeutic
targets.
Future Challenges: Regulation of Apoptosis in Animals
With the emergence of new therapeutic agents that inhibit Bcl-2
protein interactions with the aim of regulating apoptosis in
tumor development and resistance to chemotherapy, whole-
animal models would be an invaluable aid in determining the
most rational way to combine these drugs with conventional
cancer treatments. Because of the historic role of human B
cell lymphoma in the discovery and identification of Bcl-2 as
the first mammalian apoptotic regulator, it is perhaps fitting
that the Bad BH3-mimetic drug Navitoclax may find its first
use in this type of cancer. The murine lymphoma model alluded
to previously (Me´rino et al., 2012) suggests its promise in this
context. In the clinic, these cancers are traditionally treated
with a complex schedule of multiple chemotherapy agents.
Surprisingly, recent analysis of the mechanism of action of
two important drugs in the regime (Ehrhardt et al., 2011) indi-
cated that the simultaneous administration schedule used for
the last 30 years actually leads to mutual antagonism of the
Bcl-2-dependent cytotoxic effect! Using luminescence or fluo-
rescence imaging of whole tumors in mice allows potential
readouts of ‘‘final’’ effects of antitumor treatment combinations.
Although still not generally used, recent developments indicate
that we may be able to be more precise and analytical with this
approach. FRET probes have been developed with a caspase-3
cleavage site to monitor the activity of the final protease effector
of apoptosis. This probe permits real-time monitoring of
apoptosis in animals following antitumor therapy (Zhou et al.,
2010). These studies report distinct time courses of apoptosis
after different single-agent anticancer treatments, underlining
the importance of investigating these effects in the most natural
context available. Therefore, adding an inhibitor of Bcl-2 at an
arbitrary time to current treatment schedules may not be the
most rational way to modulate apoptosis. Monitoring apoptosis
in animals using FRET is not without its limitations and is
currently restricted to studying cancer cell lines and tumors at
subcutaneous sites amenable to fluorescence measurements.
Regardless, one can imagine ways of extending this technique
to look at protein-protein interactions within live animals in
multiple tissues with and without chemotherapy treatment.
Using FRET may not only permit observation of binding
between proteins, but may also provide binding dynamics as
well. With the appropriate B cell lymphoma model, such an
approach would identify the best time to switch off Bcl-2 to
maximize the proapoptotic effects of the other chemotherapy
drugs.
Thus, at all relevant levels of analysis in apoptosis research,
from protein-protein interactions using increasingly sophisti-
cated in vitro systems to investigation of whole-animal models,
the application of novel fluorescence techniques suggests that
the future is bright!ACKNOWLEDGMENTS
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